Literature DB >> 12716465

Colorectal cancers with both p16 and p14 methylation show invasive characteristics.

Kenji Hibi1, Hiroshi Nakayama, Masahiko Koike, Yasushi Kasai, Katsuki Ito, Seiji Akiyama, Akimasa Nakao.   

Abstract

Recent studies indicated that p16 and p14 inactivation owing to promoter methylation was important for colorectal tumorigenesis. In this study, we examined the methylation status of these genes in 86 primary colorectal cancers using methylation-specific PCR (MSP) and correlated the results with the clinicopathological features of the patients. Aberrant promoter methylation of p16 and p14 genes was detected in 43 of 86 (50%) and 25 of 86 (29%) colorectal cancers, respectively. Next, we examined the correlation of methylation status with the clinicopathological features. We found a significant difference in maximal tumor size (P=0.022) when patients with both p16 and p14 methylation were compared to other patients. On the other hand, there was no significant difference in other factors, such as the extent of tumor and Dukes stage. These results suggested that colorectal cancer with both p16 and p14 methylation has the same invasiveness at a smaller size compared to that of the cancer with neither p16 nor p14 methylation. Inactivation of both p16 and p14 genes may result in a malignant change in colorectal cancer cells, leading to advanced cancers with a smaller size than those with p16 or p14 activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12716465      PMCID: PMC5927110          DOI: 10.1111/j.1349-7006.2002.tb01333.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  16 in total

1.  Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status.

Authors:  M Esteller; S Tortola; M Toyota; G Capella; M A Peinado; S B Baylin; J G Herman
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

2.  AIS is an oncogene amplified in squamous cell carcinoma.

Authors:  K Hibi; B Trink; M Patturajan; W H Westra; O L Caballero; D E Hill; E A Ratovitski; J Jen; D Sidransky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

3.  Prevalence of ras gene mutations in human colorectal cancers.

Authors:  J L Bos; E R Fearon; S R Hamilton; M Verlaan-de Vries; J H van Boom; A J van der Eb; B Vogelstein
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

4.  Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors.

Authors:  S Zheng; P Chen; A McMillan; A Lafuente; M J Lafuente; A Ballesta; M Trias; J K Wiencke
Journal:  Carcinogenesis       Date:  2000-11       Impact factor: 4.944

5.  CpG island methylator phenotype in colorectal cancer.

Authors:  M Toyota; N Ahuja; M Ohe-Toyota; J G Herman; S B Baylin; J P Issa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 6.  Cancer epigenetics comes of age.

Authors:  P A Jones; P W Laird
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

7.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.

Authors:  P Cairns; T J Polascik; Y Eby; K Tokino; J Califano; A Merlo; L Mao; J Herath; R Jenkins; W Westra; J L Rutter; A Buckler; E Gabrielson; M Tockman; K R Cho; L Hedrick; G S Bova; W Isaacs; W Koch; D Schwab; D Sidransky
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

8.  Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients.

Authors:  I Nishisho; Y Nakamura; Y Miyoshi; Y Miki; H Ando; A Horii; K Koyama; J Utsunomiya; S Baba; P Hedge
Journal:  Science       Date:  1991-08-09       Impact factor: 47.728

9.  Loss of H19 imprinting in esophageal cancer.

Authors:  K Hibi; H Nakamura; A Hirai; Y Fujikake; Y Kasai; S Akiyama; K Ito; H Takagi
Journal:  Cancer Res       Date:  1996-02-01       Impact factor: 12.701

10.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  7 in total

1.  Aberrant p16((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity.

Authors:  Hiroyuki Mitomi; Naoshi Fukui; Nobuho Tanaka; Hideki Kanazawa; Tsuyoshi Saito; Takashi Matsuoka; Takashi Yao
Journal:  J Cancer Res Clin Oncol       Date:  2010-02       Impact factor: 4.553

2.  Aberrant methylation of the netrin-1 receptor genes UNC5C and DCC detected in advanced colorectal cancer.

Authors:  Kenji Hibi; Hiroki Mizukami; Atsushi Shirahata; Tetsuhiro Goto; Makiko Sakata; Yutaka Sanada
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

3.  Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer.

Authors:  T Sakakibara; K Hibi; M Koike; M Fujiwara; Y Kodera; K Ito; A Nakao
Journal:  Br J Cancer       Date:  2005-10-03       Impact factor: 7.640

4.  Relationships between p14ARF Gene Methylation and Clinicopathological Features of Colorectal Cancer: A Meta-Analysis.

Authors:  Zhangjian Zhou; Hao Zhang; Jianguo Lai; Dongmei Diao; Wenhan Li; Chengxue Dang; Yongchun Song
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

5.  The Cell Cycle-Associated Protein CDKN2A May Promotes Colorectal Cancer Cell Metastasis by Inducing Epithelial-Mesenchymal Transition.

Authors:  Wei-Kun Shi; Yun-Hao Li; Xue-Shan Bai; Guo-Le Lin
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244

6.  A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines.

Authors:  Guro E Lind; Lin Thorstensen; Tone Løvig; Gunn I Meling; Richard Hamelin; Torleiv O Rognum; Manel Esteller; Ragnhild A Lothe
Journal:  Mol Cancer       Date:  2004-10-11       Impact factor: 27.401

7.  CDH13 promoter region is specifically methylated in poorly differentiated colorectal cancer.

Authors:  K Hibi; H Nakayama; Y Kodera; K Ito; S Akiyama; A Nakao
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.